Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Endometrial Neoplasms 2Breast Neoplasms 2Smoking 1Rectal Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Peripheral Nervous System Diseases 1Overweight 1Obesity 1Motor Activity 1Meningioma 1Medulloblastoma 1Lymphoma, Mantle-Cell 1Lymphoma 1Localized Prostate Cancer 1Leukemia, Myeloid, Acute 1Leukemia 1Infertility 1HER2 IHC3+ Advanced Colorectal Cancer 1Genetic Diseases, Inborn 1Cognitive Dysfunction 1

Interventions

Fulvestrant 64Letrozole 54Paclitaxel 49Trastuzumab 41pembrolizumab 40ribociclib 37Specimen Handling 37palbociclib 36Capecitabine 34Anastrozole 34Carboplatin 33Tamoxifen 32exemestane 30pertuzumab 28abemaciclib 28Magnetic Resonance Spectroscopy 26Cyclophosphamide 26trastuzumab deruxtecan 24Surveys and Questionnaires 21Biopsy 19Radiotherapy 18olaparib 17Blood Specimen Collection 17Standard of Care 16Docetaxel 16Taxes 14Mastectomy, Segmental 14eribulin 13elacestrant 13Methods 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Tablets × 90 days × Clear all
NCT05392608 2026-05-22

SEQUEL-Breast

Borstkanker Onderzoek Groep

Phase 2 Active not recruiting
130 enrolled
Breast

Breast Neoplasms, Genetic Diseases, Inborn

NCT04055493 2026-05-11

ADAPTcycle

West German Study Group

Phase 3 Active not recruiting
1,684 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡